VIVS · VivoSim Labs, INC.
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm included in its opinion for the year ended March 31, 2026 an explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available.”View the 10-Q filed Aug 12, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Mar 21, 2025; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VIVS
this stock
VivoSim Labs, INC.
|
$4.79M | -82.2% | +8.8% | — | 3.8% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Mar 21, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VIVS | -31.1% | -44.4% | -83.6% | -5.2% | -82.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -31.5% | -48.9% | -97.4% | -9.1% | -96.0% |